The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to ...
The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, ...
Die amerikanische Bundesbehörde Federal Trade Commission (FTC) stellt Patenteinträge für Ozempic, Victoza, Saxenda und ...
Federal antitrust officials have redoubled efforts to challenge what they see as improper pharma patent listings that delay the ...
The Federal Trade Commission (FTC) continues slicing a machete through the patent thicket. On Tuesday, the agency sent warning ...
On April 30, 2024, the Federal Trade Commission (FTC) announced that it sent a new set of warning letters to ten pharmaceutical ...
The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more. The Federal Trade Commission is challenging ...